Company Overview and News

0
PH 7-Eleven operator reports 6-month profit growth of 19.4%

2018-07-13 business.inquirer.net
The country’s leading convenience store operator, Philippine Seven Corp. (PSC), grew its net profit in the first six months by 19.4 percent year-on-year to P533.2 million, citing the favorable impact of recent individual income tax cuts on consumer spending.
PSKXF SEVN PHSXY PSE PHSVY

0
Philippine Seven Q2 earnings jump

2018-07-13 bworldonline
THE local licensee of the 7-Eleven convenience store chain saw its net income jump by 18.9% in the second quarter of 2018, driven by higher sales and more operating stores for the period.
SEVN PHSVY

0
Philippine Seven reports higher profit, sales in second quarter

2018-07-13 bworldonline
The local licensee of the chain of 7-Eleven convenience stores saw its net income jump by 18.9% in the second quarter of 2018, driven by the strong performance of existing stores.
SEVN PHSVY

5
Corporate Earnings Roundup (05/16/18)

2018-05-15 bworldonline
PHILIPPINE Seven Corp. (PSC) saw its profits jump 20.5% in the first quarter, driven by higher sales at its network of 7-Eleven convenience stores which was attributed to the “favorable” impact of the tax reform law.
PSKXF GERI SEVN PHSXY PSE PHSVY

5
Puregold: Pace of Lawson expansion was too slow

2018-05-13 bworldonline
PUREGOLD PRICE Club, Inc. chose to divest from the Lawson chain of convenience stores after its Japanese partner failed to deliver on its expansion program.
PGCMF ITOCY SSI ITOCF AYAAY SEVN PHSVY PRGLY PGOLD ALI AYAAF

5
Puregold exits convenience store sector, sells stake in Lawson

2018-04-27 business.inquirer.net
Retail magnate Lucio Co-led Puregold Price Club Inc. is bowing out of the convenience store business three years after debuting into this highly competitive segment, choosing to focus on the battleground for supermarkets.
PSKXF RBNTF RRETY SEVN PHSXY PSE PHSVY RRHI

1
Firms see robust sales despite TRAIN

2018-04-15 bworldonline
FILIPINOS did not hold back on spending despite higher prices of goods in the first quarter of the year, but elevated input costs would continue to put pressure on the profitability of consumer companies.
PGCMF SEVN PHSVY PRGLY COL PGOLD

0
Strong Q4 sales boost Philippine Seven profit

2018-04-04 bworldonline
THE Philippine licensee of the 7-Eleven chain of convenience stores relied on the strength of a strong fourth-quarter performance to turn in a double-digit growth in earnings last year.
SEVN PHSVY

5
PH 7-Eleven operator nets P1.32B

2018-04-04 business.inquirer.net
The country’s leading convenience store operator Philippine Seven Corp. (PSC) saw a 12.1-percent growth in net profit last year to P1.32 billion, as full-year earnings were shored up by robust business in the fourth quarter.
PSKXF SEVN PHSXY PSE PHSVY

19
PSEi gains 0.59%, closes at 8,238.15

2018-03-16 business.inquirer.net
The local stock barometer firmed up above 8,200 on Friday as the recent market pullback attracted some bargain-hunting among local investors who picked up stocks dumped by foreign players.
SVTMF PSKXF AYAAY SEVN SM SECB SMIVY SYBJF PHSXY PSE PHSVY ALI AYAAF

19
PSEi firms up at 8,200

2018-03-16 business.inquirer.net
The local stock barometer firmed up above 8,200 on Friday as the recent market pullback attracted bargain-hunting among local investors who picked up stocks dumped by foreign players.
SVTMF PSKXF AYAAY SEVN SM SECB SMIVY SYBJF PHSXY PSE PHSVY ALI AYAAF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

44m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 71828P105